Abstract
The treatment of unresectable/metastatic cholangiocellular carcinoma (CCC) is limited and the response rate of chemotherapy is unsatisfactory. Apatinib, a novel antiangiogenic agent targeting vascular endothelial growth factor receptor (VEGFR2), is currently being studied in different tumors. This study was performed to assess the response rate and safety of apatinib in patients with unresectable/metastatic CCC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have